JessicaJLinMD

We are pleased to share this article out today in @CD_AACR on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound mutations 🔥Fills an important unmet need for pts with ALK+ lung cancer and other solid tumors 📢Tune in for updated prelim efficacy&safety data from the global ongoing phase I/II study (ALKOVE-1) of NVL-655 to be presented TOMORROW at #ESMO2024! @ALKPositiveinc @ALKpositiveINT @MGHCancerCenter @MassGeneralNews @alexdrilon @MSKCancerCenter @BenjaminBesseMD @MLJohnsonMD2 @DRCamidge @jii_bum_lee @ViolaWZhu aacrjournals.org/cancerdiscover…

@BalazsHalmosMD @carnegiehall Amazing!

When the fiddler (and what an amazing fiddler!) is under the roof! @carnegiehall

Update for RET NSCLC @CCR_AACR describes acquired resistance to selective RET inhibitors. The "RETgistry" included 109 pts with post-SRI biopsies and showed 14% with secondary RET mutations. Off target included MET (18%), KRAS (7%), CDKN2A/B (5%). aacrjournals.org/clincancerres/…

Collaborative study between MGB Thoracic and Haber, Mishra, Toner and Maheswaran labs shows DLL3 CTCs are highly predictive for outcomes with tarlatamab in SCLC. Also provide insights into CRS and mechanisms of resistance. aacrjournals.org/cancerdiscover…

Join us in downtown Washington, DC on Saturday October 4th for the DC Lung Cancer Conference, an @IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25 Register today at medstarhealth.org/dclung25

@triparnasen Congratulations!! 🎊🎉🍾

Professor with Tenure! So thankful for my mentors, colleagues, & collaborators who made this milestone possible! Nothing but deep gratitude to the amazing trainees, past & present, who made the science & the journey meaningful. Excited for what lies ahead, here is to the future... @OSUCCC_James @OhioStateMedOnc @OSUWexMed @OhioStateWIMS @OhioStatePIIO @OncLive @OncoAlert @oncodaily #LCSM #WomeninAcademia #WomeninSTEM #SCLC #NSCLC #lungcancer

Despite progress, advanced ALK+ lung cancer almost always recurs. By deeply exploring the biology of cancer cells that resist treatment, the new PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to bend the survival curve for patients - @JessicaJLinMD #RadicalCollaboration @DanaFarber, @MDAndersonNews, @kochinstitute ,@hopkinskimmel, @MSKCancerCenter, @BostonChildrens, @MGHCancerCenter, @CUCancerCenter, @VUMC_Cancer & @ALKPositiveinc

Tackling big problems requires radical collaboration 💪. The “PoweRD 2 Cure” team strives to overcome minimal residual disease (MRD) observed with #targetedtherapy in #lungcancer. Powerhouse team to conquer an urgent, unmet clinical question. @break_cancer @ALKPositiveinc

Dr. @SWaliany is one of our abstract award winners for the DF/HCC lung cancer symposium - she discussed mechanisms of resistance to first-line vs. later-line Alectinib for ALK + NSCLC @ALKPositiveinc @ALKpositiveINT @JessicaJLinMD @LeciaSequist

Stage III ALK+ NSCLC: consolidation ALK TKI v Durva v Obs @JTOonline: -67pts, ALKi=15 Durva=30 obs=22 -mrwPFS favors ALKi (NR, 95%CI 22.7-NR) v durva (11.3m HR 0.12 p=0.006) v obs (7.2m HR=0.04 p<0.0001) Small n, but useful @OncoAlert @AminNassarMD #LCSM jto.org/article/S1556-…

Nice of @JCO_ASCO to publish this acknowledgment of reviewers for 2024. The peer review process is not perfect - it takes a lot of time to properly review submitted manuscripts and this is uncompensated time. But I think there are real benefits - individually and to the field.

We are excited to share the updated efficacy&safety data of #Zidesamtinib (NVL-520), a next-generation ROS1-selective, TRK-sparing, brain-penetrant inhibitor in ROS1 fusion+ solid tumors, from the ongoing #ARROS1 global phase 1/2 trial, presented today #ESMO24 by @BenjaminBesseMD 👉 MTD not reached, RP2D selected (100 mg oral daily) 🔥 ORR 44% in pts who were heavily pretreated (1-4 prior ROS1 inhibitors), 51% if repotrectinib-naive 🔥 ORR 41% in pts who received 2 or more prior ROS1 TKIs 🔥 ORR 38% in pts post-repotrectinib and with ROS1 G2032R mutation (the most common on-target mutation resistant to earlier-generation ROS1 TKIs) ✅ CNS-active with IC-ORR of 50%, including in pts post-lorlatinib / post-repotrectinib 🌟 Safety profile very favorable, well tolerated by pts notably with sparing of TRK-mediated neuro-toxicity (‼️important in the ROS1 treatment landscape‼️) Encouraging results, warranting further investigation including in TKI-naive and TKI-pretreated settings 👏 Congratulations to @BenjaminBesseMD on the presentation 🙏 Grateful to co-investigators and patients, families and caregivers @alexdrilon B.C. Cho @DRCamidge @JoelNealMD C.C. Lin @StephenVLiu @MNagasaka S. Kao @EnriquetaFelip A.J. van der Wekken J. Bauman @ShirishGadgeel @ViolaWZhu @MGHCancerCenter @MassGeneralNews @GustaveRoussy @MSKCancerCenter @ros1cancer #LCSM

Responses were durable, also with CNS activity including post-progression on lorlatinib, and importantly, favorable safety and tolerability overall c/w ALK selective design 📢 Phase II study ALKOVE-1 is ongoing, evaluating NVL-655 in pts who are TKI-naive AND TKI-pretreated 👏Congratulations to @alexdrilon on the presentation 🙏Grateful to co-investigators @MLJohnsonMD2 @LuisPaz_Ares @BenjaminBesseMD @JulienMazieres @Joshua_Reuss @bensolomon1 @DRCamidge @EnriquetaFelip @Anna_Minchom @ShirishGadgeel @ViolaWZhu Geoffrey Liu A. Swalduz C.S. Baik and others 🙏Always deeply, deeply thankful to patients, families, and caregivers for their courage and hope and participating in this #ALKOVE-1 study, many of whom travel long distances to do so @ALKPositiveinc @ALKpositiveINT @ALKNEWS @MassGeneralNews @MGHCancerCenter @MSKCancerCenter @HenryPelish

🌟And here with the efficacy and safety data of #NVL655, ALK-selective, TRK-sparing and brain-penetrant 4G ALK TKI, from ALKOVE-1, presented today #ESMO24 by @alexdrilon ✅ ORR 38% in heavily pretreated pts overall (1-5 prior ALK TKIs) ✅ ORR 35% in pts post-lorlatinib (in which setting we currently have no approved ALK TKIs) --> 50-64% in pts with single or compound ALK resistance mutations ✅ ORR 57% in pts lorlatinib-naive

1/4 Alright, so here are my thoughts on Radiation to Residual Disease after Targeted Therapies as presented at #WCLC24. Focusing on EGFR mutant #lungcancer where we all agree, I think, that osimertinib alone cannot be the answer, right⁉️🧐 The main risk here is secondary dissemination of drug resistance clones (DF1) from originally involved anatomical sites (OF) that happens before local therapy is employed eradicate clinical oligoprogression⚠️ @SusanScottMD #LCSM

🏹Must improve biomarker testing to identify patients who can benefit from effective therapeutic agents like Larotrectinib and to increase their reach to patients! 🙏Thankful to all investigators involved in these studies 🙏 Most importantly thankful to patients and caregivers whose generosity, strength and courage, and hope and faith in research enable advances #LCSM [6/6]

Larotrectinib is a very well-tolerated drug overall among patients in the clinic, and the updated analysis continues to support this ☑️TEAE and TRAE profile consistent with prior reports ☑️Predominantly grade 1/2 AEs ☑️One patient discontinued tx due to TRAE (increased liver enzymes) [5/6]

Pleased to share an updated efficacy, safety, and biomarker analysis of Larotrectinib in TRK fusion+ NSCLC, presented at the #WCLC24 today [1/6]